Artivion, Inc. (AORT)

NYSE • Healthcare

$23.3

-$0.66 (-2.8%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$23.86

Day Range$22.91 - $24.2

Avg. Volume (3M)496.8K

Market Cap$1.1B

52 Week Range

$19.16$48.25

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$125.7M100%

Gross Profitminus cost of goods$80.5M64%

In plain terms: out of every $100 in revenue, Artivion, Inc. currently loses $11.

Fundamentals & Financials

Revenue (TTM)

$471.4M

Net Income (TTM)

-$3.1M

EPS (TTM)

-$0.06

ROA (TTM)

-0.3%

Current Ratio

3.47

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-72.5%Q3 2025$0.03

+14.3%Q4 2025$0.16

-63.6%Q1 2026$0.05

-50.0%Q2 2026$0.03

-11300.0%Q3 2026-$0.28

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -11300.0%

Artivion beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 6 based on preliminary results, as adjusted EPS of $0.13 topped the $0.00 estimate by about +5100% and revenue of about $125.8 million came in roughly 5% above the $120.0 million consensus. Revenue rose 11.3% from about $113.0 million a year ago, while gross profit reached about $80.5 million and gross margin held near 64%. Adjusted EPS was down 45.8% from $0.24 in the prior-year quarter. Operating cash flow was negative $112,000. For the next period, consensus calls for EPS of $0.13 on revenue of $121.5 million.

Next report — what to expect

Artivion, Inc. (AORT) reports earnings on November 5, 2026. Wall Street is looking for EPS of -$0.061 on revenue of $120.9 million; for trailing context, revenue grew +11.3% year over year last quarter. Over its most recent quarters, Artivion has beaten EPS in 1 of 8.

View full earnings history

About Artivion, Inc.

Artivion, Inc. develops and sells implantable and preservation products for cardiac and vascular surgery as a healthcare company listed on the NYSE under AORT. Formerly CryoLife, the company generates $441.3 million of revenue in FY2025 from a portfolio centered on aortic repair, surgical sealants, tissue patches, valves, and preservation services.

Name

Artivion, Inc.

CEO

James Patrick Mackin

Website

artivion.com

Industry

Healthcare

Year Founded

1984

Employees

1,800

Today's Snapshot

AI-generated

AORT closed 2.8% below yesterday's close, in line with a weaker sector. AORT reports earnings on 5 November.

Trading Volume

Below 10d avg (506.6K)

415.3K

vs S&P 500 Today

Underperforming Market

-2.28%

Updated: October 23, 2026 at 20:24 UTC

Technical Indicators

2 Buy2 Neutral4 Sell

AORT’s bias is bearish despite some short-term strength, with ADX showing a modestly firm trend and several short-term moving averages trading below longer-term averages. Momentum is mixed—CCI and short momentum readings are bullish while Stochastic flags an overbought condition and MACD is flat—while the 200-day average remains well above the market, highlighting longer-term downside pressure. Volume-based OBV reads positive, suggesting buying interest, but ATR implies typical intraday range. Classic pivot sits slightly above the price, leaving near-term resistance intact. Technical takeaway: Sell.

All signals